Exhibit 5.1
[Lowenstein Sandler LLP letterhead]
November 6, 2020
Celldex Therapeutics, Inc.
Perryville III Building
53 Frontage Road, Suite 220
Hampton, NJ 08827
Re:
Shelf Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to Celldex Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with its filing of a shelf registration statement on Form S-3 (the “Registration Statement”), including the base prospectus constituting a part thereof (the “Base Prospectus”) and the sale agreement prospectus that is part of the Registration Statement (the “ATM Prospectus”), to which this opinion is attached, filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”). We have been requested by the Company to render this opinion in connection with the filing of the Registration Statement.
The Base Prospectus provides that it will be supplemented in the future by one or more supplements to the Base Prospectus (each a “Prospectus Supplement”). The Base Prospectus, as supplemented by various Prospectus Supplements, will provide for the registration by the Company of (i) shares of preferred stock, par value $0.01 per share, in one or more series or classes (the “Preferred Stock”), (ii) shares of common stock, par value $0.001 per share, (the “Common Stock”), (iii) warrants to purchase Common Stock or Preferred Stock (the “Warrants”), (iv) depositary shares (evidenced by depositary receipts) representing fractional interests in shares of Common Stock or Preferred Stock (the “Depositary Shares”), or (v) units composed of the foregoing (the “Units”). The Preferred Stock, Common Stock, Warrants, Depositary Shares and the Units are collectively referred to herein as the “Securities.” The Preferred Stock may be exchangeable for and/or convertible into shares of Common Stock or another series of Preferred Stock. The Units may be exchangeable and/or settled into the Securities comprising the Units.
The ATM Prospectus relates to the sale by the Company of shares of Common Stock having an aggregate offering price of up to $50,000,000 (the “ATM Shares”) under the Controlled Equity OfferingSM Sales Agreement, dated as of May 19, 2016 (the “Sales Agreement”) by and between the Company and Cantor Fitzgerald & Co., as sales agent. We understand that the ATM Shares are to be issued by the Company and sold by Cantor Fitzgerald & Co. pursuant to the Sales Agreement, as described in the Registration Statement and the ATM Prospectus.
In rendering our opinion, we have reviewed the Sales Agreement, the Registration Statement and the exhibits thereto. We have also reviewed such corporate documents and records of the Company, such certificates of public officials and officers of the Company and such other matters as we have deemed necessary or appropriate for purposes of this opinion.
Except to the extent we opine as to the binding effect of certain documents as set forth in paragraphs 4, 5 and 6 below, we have assumed that all documents referenced below are the valid and binding obligations of and enforceable against the parties thereto. We have also assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the conformity to authentic original documents of all documents submitted to us as certified, conformed or photostatic copies and the legal capacities of all natural persons.
Based on the foregoing, and subject to the assumptions, limitations and qualifications set forth herein, we are of the opinion that:
1.
(a) When a new class or series of Preferred Stock has been duly established in accordance with the terms of the restated certificate of incorporation of the Company, as amended (“Charter”), the by-laws of the Company (“Bylaws”) and applicable law (in the event that the Preferred Stock is a